VIB accelerates therapeutic biologics discovery with geneious biologics

12 November 2018
Geneious Biologics, an enterprise software solution for companies engaged in screening of antibodies and antibody-like molecules, has been chosen by VIB to support therapeutic biologics discovery at its Discovery Sciences group.

B
runo Dombrecht, Expert Scientist at VIB Discovery Sciences: “Geneious Biologics will help us scale-up our screening efforts. We are incorporating more high-throughput sequencing into our core business, and are screening increasingly large quantities of unique and complex VHH-based multi-specific biologics.  We sought a bioinformatics platform that provides powerful, fast and deep sequence analysis and, importantly, allows us to consolidate and manage our sequence data in a secure environment that can be shared with our partners.”

VHHs are an extremely versatile class of molecules for research, diagnostics and therapeutics in human and animal health. This powerful technology was discovered at the Vrije Universiteit Brussel and continues to be the subject of intensive research at VIB and at VIB Discovery Sciences, also available to academic and commercial partners through VIB’s Core Facilities.

Geneious Biologics, is a cloud-based enterprise software solution for analysis of antibodies and related constructs using DNA sequence data.
The software applies intuitive visualization tools and advanced analytics to help specialist biologic drug development companies accelerate identification of therapeutic candidates.

“We are proud to be working with VIB Discovery Sciences to support their mission critical workflows around therapeutic biologics screening, analysis and discovery. This is an exciting therapeutic area with much potential to solve unmet medical needs,” said
Jannick Bendtsen, Vice President of Technology Services, Geneious Biologics.​

“It is exciting to partner with institutes like VIB to help drive their biologic research and development goals. In leveraging the full power of the Geneious Biologics platform customers will make better, data driven discoveries, and bring successful biologics to market faster.”